XTL Biopharmaceuticals delays annual Form 20-F filing amid subsidiary liquidation proceedings

• XTL Biopharmaceuticals filed a Form 12b-25 to delay its annual report on Form 20-F for fiscal year ended Dec. 31, 2025.
• Filing delay was tied to liquidation proceedings at wholly owned unit The Social Proxy.
• Company cited lack of operational and financial data from subsidiary needed to complete audited financial statements and related disclosures.
• XTL expects to file Form 20-F once subsidiary information becomes available or once court or regulatory guidance allows omission of that information.
• Company did not anticipate a significant change in results of operations versus prior-year period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XTL Biopharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-050305), on April 30, 2026, and is solely responsible for the information contained therein.